Literature DB >> 25592552

Genetic variants are not associated with outcome in patients with coronary artery disease and left ventricular dysfunction: results of the Genetic Substudy of the Surgical Treatment for Ischemic Heart Failure (STICH) trials.

Arthur M Feldman1, Lilin She, Dennis M McNamara, Douglas L Mann, Michael R Bristow, Alan S Maisel, Daniel R Wagner, Bert Andersson, Luigi Chiariello, Christopher S Hayward, Paul Hendry, John D Parker, Normand Racine, Craig H Selzman, Michele Senni, Janina Stepinska, Marian Zembala, Jean Rouleau, Eric J Velazquez, Kerry L Lee.   

Abstract

OBJECTIVES AND
BACKGROUND: We evaluated the ability of 23 genetic variants to provide prognostic information in patients enrolled in the Genetic Substudy of the Surgical Treatment for Ischemic Heart Failure (STICH) trials.
METHODS: Patients assigned to STICH Hypothesis 1 were randomized to medical therapy with or without coronary artery bypass grafting (CABG). Those assigned to STICH Hypothesis 2 were randomized to CABG or CABG with left ventricular reconstruction.
RESULTS: In patients assigned to STICH Hypothesis 2 (n = 714), no genetic variant met the prespecified Bonferroni-adjusted threshold for statistical significance (p < 0.002); however, several variants met nominal prognostic significance: variants in the β2-adrenergic receptor gene (β2-AR Gln27Glu) and in the A1-adenosine receptor gene (A1-717 T/G) were associated with an increased risk of a subject dying or being hospitalized for a cardiac problem (p = 0.027 and 0.031, respectively). These relationships remained nominally significant even after multivariable adjustment for prognostic clinical variables. However, none of the 23 genetic variants influenced all-cause mortality or the combination of death or cardiovascular hospitalization in the STICH Hypothesis 1 population (n = 532) by either univariate or multivariable analysis.
CONCLUSION: We were unable to identify the predictive genotypes in optimally treated patients in these two ischemic heart failure populations.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25592552      PMCID: PMC4367125          DOI: 10.1159/000368221

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  33 in total

1.  Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure.

Authors:  D M McNamara; R Holubkov; K Janosko; A Palmer; J J Wang; G A MacGowan; S Murali; W D Rosenblum; B London; A M Feldman
Journal:  Circulation       Date:  2001-03-27       Impact factor: 29.690

2.  A common variant of the AMPD1 gene predicts improved cardiovascular survival in patients with coronary artery disease.

Authors:  J L Anderson; J Habashi; J F Carlquist; J B Muhlestein; B D Horne; T L Bair; R R Pearson; N Hart
Journal:  J Am Coll Cardiol       Date:  2000-10       Impact factor: 24.094

3.  Pharmacogenomics--drug disposition, drug targets, and side effects.

Authors:  William E Evans; Howard L McLeod
Journal:  N Engl J Med       Date:  2003-02-06       Impact factor: 91.245

4.  Effect of the Asp298 variant of endothelial nitric oxide synthase on survival for patients with congestive heart failure.

Authors:  Dennis M McNamara; Richard Holubkov; Lisa Postava; Ravi Ramani; Karen Janosko; Michael Mathier; Guy A MacGowan; Srinivas Murali; Arthur M Feldman; Barry London
Journal:  Circulation       Date:  2003-03-17       Impact factor: 29.690

5.  Evaluation of the aldosterone synthase (CYP11B2) gene polymorphism in patients with myocardial infarction.

Authors:  C Hengstenberg; S R Holmer; B Mayer; H Löwel; S Engel; H W Hense; G A Riegger; H Schunkert
Journal:  Hypertension       Date:  2000-03       Impact factor: 10.190

6.  Prognostic impact of matrix metalloproteinase gene polymorphisms in patients with heart failure according to the aetiology of left ventricular systolic dysfunction.

Authors:  Frédérique Mizon-Gérard; Pascal de Groote; Nicolas Lamblin; Xavier Hermant; Jean Dallongeville; Philippe Amouyel; Christophe Bauters; Nicole Helbecque
Journal:  Eur Heart J       Date:  2004-04       Impact factor: 29.983

7.  Lack of association between the insertion/deletion polymorphism of the angiotensin-converting enzyme gene and idiopathic dilated cardiomyopathy.

Authors:  H E Montgomery; P J Keeling; J H Goldman; S E Humphries; P J Talmud; W J McKenna
Journal:  J Am Coll Cardiol       Date:  1995-06       Impact factor: 24.094

8.  Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy.

Authors:  M V Raynolds; M R Bristow; E W Bush; W T Abraham; B D Lowes; L S Zisman; C S Taft; M B Perryman
Journal:  Lancet       Date:  1993-10-30       Impact factor: 79.321

9.  Effects of tumor necrosis factor gene polymorphisms on patients with congestive heart failure. VEST Investigators for TNF Genotype Analysis. Vesnarinone Survival Trial.

Authors:  T Kubota; D M McNamara; J J Wang; M Trost; C F McTiernan; D L Mann; A M Feldman
Journal:  Circulation       Date:  1998-06-30       Impact factor: 29.690

10.  Decreased levels of BAG3 in a family with a rare variant and in idiopathic dilated cardiomyopathy.

Authors:  Arthur M Feldman; Rene L Begay; Tijana Knezevic; Valerie D Myers; Dobromir B Slavov; Weizhong Zhu; Katherine Gowan; Sharon L Graw; Kenneth L Jones; Douglas G Tilley; Ryan C Coleman; Paul Walinsky; Joseph Y Cheung; Luisa Mestroni; Kamel Khalili; Mathew R G Taylor
Journal:  J Cell Physiol       Date:  2014-11       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.